These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38140932)

  • 1. Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey.
    Aygüneş U; Karagun BS; Ay Tuncel D; Sasmaz HI; Antmen B
    Exp Clin Transplant; 2023 Nov; 21(11):883-892. PubMed ID: 38140932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
    Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
    Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
    Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
    Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
    Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
    Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
    Bernardo ME; Piras E; Vacca A; Giorgiani G; Zecca M; Bertaina A; Pagliara D; Contoli B; Pinto RM; Caocci G; Mastronuzzi A; La Nasa G; Locatelli F
    Blood; 2012 Jul; 120(2):473-6. PubMed ID: 22645178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
    Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
    Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
    Khandelwal P; Yeh RF; Yu L; Lane A; Dandoy CE; El-Bietar J; Davies SM; Grimley MS
    Transplantation; 2021 Apr; 105(4):891-896. PubMed ID: 32467478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
    Huttunen P; Taskinen M; Vettenranta K
    Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
    Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    Bernardo ME; Zecca M; Piras E; Vacca A; Giorgiani G; Cugno C; Caocci G; Comoli P; Mastronuzzi A; Merli P; La Nasa G; Locatelli F
    Br J Haematol; 2008 Nov; 143(4):548-51. PubMed ID: 18986389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool.
    van der Stoep MYEC; Berghuis D; Bredius RGM; Buddingh EP; Mohseny AB; Smiers FJW; Guchelaar HJ; Lankester AC; Zwaveling J
    Sci Rep; 2021 Sep; 11(1):19084. PubMed ID: 34580398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
    Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
    Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts.
    Mathews V; George B; Viswabandya A; Abraham A; Ahmed R; Ganapule A; Sindhuvi E; Lakshmi KM; Srivastava A
    PLoS One; 2013; 8(4):e61637. PubMed ID: 23637873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Treosulfan- or Busulfan-Based Conditioning in Pediatric Patients with Acute Leukemia or Myelodysplastic Syndrome: Results of an Associazione Italiana Ematologia Oncologia Pediatrica Retrospective Study.
    Saglio F; Pagliara D; Zecca M; Balduzzi A; Cattoni A; Prete A; Tambaro FP; Faraci M; Calore E; Locatelli F; Fagioli F;
    Transplant Cell Ther; 2024 Apr; 30(4):433.e1-433.e10. PubMed ID: 38176654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.